Eagle Depreciation Amortization and Accretion vs Issuance Purchase of Equity Shares Analysis

EGRX Stock

USD 5.20 0.61 13.29%

Trend analysis of Eagle Pharmaceuticals balance sheet accounts such as Other Current Liabilities of 103.7 M or Total Current Liabilities of 134.1 M provides information on Eagle Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Eagle Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Eagle Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Total Assets Non Current Assets Total

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.

About Eagle Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Eagle Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Eagle Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Eagle Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Eagle currently owns. An asset can also be divided into two categories, current and non-current.

Eagle Pharmaceuticals Balance Sheet Chart

Eagle Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Eagle Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, Eagle Pharmaceuticals' Other Assets are fairly stable compared to the past year. Long Term Debt is likely to rise to about 67.9 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 41.6 M in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Eagle Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Eagle Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Eagle Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Eagle Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Eagle Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eagle Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.At this time, Eagle Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 31.1 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop 5.03 in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	1.6M	4.0M	4.7M	4.9M
Depreciation And Amortization	3.8M	12.0M	13.8M	14.5M

Interest Expense Depreciation And Amortization

Eagle Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		0.65	0.82	0.92	0.89	0.39	0.79	-0.02	0.94	0.93	0.64	0.96	0.81	0.93	0.91	0.63	0.98	0.8	0.66	-0.24	0.93	0.86	0.77	0.1	0.96	0.9
Short Long Term Debt Total	0.65		0.58	0.53	0.7	0.3	0.44	-0.11	0.48	0.59	0.41	0.6	0.4	0.55	0.46	0.43	0.66	0.75	0.55	0.26	0.68	0.55	0.57	0.52	0.59	0.52
Other Current Liab	0.82	0.58		0.94	0.56	0.06	0.45	0.42	0.63	0.83	0.15	0.92	0.75	0.88	0.69	0.14	0.74	0.46	0.39	-0.18	0.84	0.95	0.46	0.09	0.92	0.81
Total Current Liabilities	0.92	0.53	0.94		0.7	0.13	0.66	0.27	0.82	0.93	0.36	0.96	0.85	0.94	0.88	0.34	0.84	0.59	0.43	-0.2	0.85	0.98	0.61	-0.03	0.97	0.93
Total Stockholder Equity	0.89	0.7	0.56	0.7		0.48	0.87	-0.32	0.89	0.79	0.79	0.77	0.66	0.77	0.8	0.77	0.9	0.92	0.73	-0.25	0.78	0.63	0.86	0.24	0.76	0.76
Property Plant And Equipment Net	0.39	0.3	0.06	0.13	0.48		0.19	-0.56	0.33	0.34	0.71	0.22	-0.04	0.14	0.31	0.69	0.45	0.48	0.74	-0.44	0.37	0.0	0.58	0.5	0.24	0.4
Current Deferred Revenue	0.79	0.44	0.45	0.66	0.87	0.19		-0.12	0.91	0.69	0.61	0.72	0.68	0.73	0.82	0.58	0.78	0.69	0.43	-0.17	0.65	0.58	0.8	-0.21	0.7	0.66
Net Debt	-0.02	-0.11	0.42	0.27	-0.32	-0.56	-0.12		-0.07	0.09	-0.74	0.24	0.18	0.21	0.04	-0.74	-0.07	-0.46	-0.53	0.17	0.17	0.33	-0.26	-0.54	0.25	0.04
Retained Earnings	0.94	0.48	0.63	0.82	0.89	0.33	0.91	-0.07		0.82	0.69	0.87	0.83	0.87	0.93	0.67	0.93	0.75	0.53	-0.22	0.84	0.74	0.76	-0.15	0.87	0.81
Accounts Payable	0.93	0.59	0.83	0.93	0.79	0.34	0.69	0.09	0.82		0.46	0.93	0.73	0.92	0.86	0.45	0.88	0.71	0.58	-0.23	0.81	0.86	0.75	0.13	0.92	0.95
Cash	0.64	0.41	0.15	0.36	0.79	0.71	0.61	-0.74	0.69	0.46		0.4	0.38	0.4	0.61	0.99	0.68	0.81	0.76	-0.3	0.49	0.27	0.68	0.32	0.42	0.53
Non Current Assets Total	0.96	0.6	0.92	0.96	0.77	0.22	0.72	0.24	0.87	0.93	0.4		0.84	0.98	0.86	0.38	0.91	0.65	0.5	-0.2	0.93	0.92	0.67	-0.01	0.99	0.88
Non Currrent Assets Other	0.81	0.4	0.75	0.85	0.66	-0.04	0.68	0.18	0.83	0.73	0.38	0.84		0.91	0.78	0.37	0.74	0.54	0.25	-0.07	0.71	0.84	0.36	-0.23	0.83	0.73
Other Assets	0.93	0.55	0.88	0.94	0.77	0.14	0.73	0.21	0.87	0.92	0.4	0.98	0.91		0.83	0.38	0.87	0.64	0.46	-0.18	0.85	0.9	0.6	-0.04	0.95	0.86
Long Term Debt	0.91	0.46	0.69	0.88	0.8	0.31	0.82	0.04	0.93	0.86	0.61	0.86	0.78	0.83		0.59	0.88	0.67	0.45	-0.17	0.82	0.82	0.75	-0.17	0.9	0.91
Cash And Short Term Investments	0.63	0.43	0.14	0.34	0.77	0.69	0.58	-0.74	0.67	0.45	0.99	0.38	0.37	0.38	0.59		0.66	0.83	0.73	-0.23	0.49	0.26	0.66	0.34	0.41	0.51
Net Receivables	0.98	0.66	0.74	0.84	0.9	0.45	0.78	-0.07	0.93	0.88	0.68	0.91	0.74	0.87	0.88	0.66		0.82	0.73	-0.26	0.93	0.79	0.77	0.11	0.91	0.84
Common Stock Total Equity	0.8	0.75	0.46	0.59	0.92	0.48	0.69	-0.46	0.75	0.71	0.81	0.65	0.54	0.64	0.67	0.83	0.82		0.75	-0.1	0.69	0.54	0.76	0.44	0.64	0.65
Common Stock Shares Outstanding	0.66	0.55	0.39	0.43	0.73	0.74	0.43	-0.53	0.53	0.58	0.76	0.5	0.25	0.46	0.45	0.73	0.73	0.75		-0.53	0.58	0.36	0.66	0.61	0.5	0.54
Short Term Investments	-0.24	0.26	-0.18	-0.2	-0.25	-0.44	-0.17	0.17	-0.22	-0.23	-0.3	-0.2	-0.07	-0.18	-0.17	-0.23	-0.26	-0.1	-0.53		-0.18	-0.12	-0.27	-0.13	-0.21	-0.28
Non Current Liabilities Total	0.93	0.68	0.84	0.85	0.78	0.37	0.65	0.17	0.84	0.81	0.49	0.93	0.71	0.85	0.82	0.49	0.93	0.69	0.58	-0.18		0.81	0.69	0.07	0.94	0.78
Inventory	0.86	0.55	0.95	0.98	0.63	0.0	0.58	0.33	0.74	0.86	0.27	0.92	0.84	0.9	0.82	0.26	0.79	0.54	0.36	-0.12	0.81		0.49	-0.03	0.94	0.86
Other Current Assets	0.77	0.57	0.46	0.61	0.86	0.58	0.8	-0.26	0.76	0.75	0.68	0.67	0.36	0.6	0.75	0.66	0.77	0.76	0.66	-0.27	0.69	0.49		0.21	0.68	0.74
Other Stockholder Equity	0.1	0.52	0.09	-0.03	0.24	0.5	-0.21	-0.54	-0.15	0.13	0.32	-0.01	-0.23	-0.04	-0.17	0.34	0.11	0.44	0.61	-0.13	0.07	-0.03	0.21		-0.02	0.1
Total Liab	0.96	0.59	0.92	0.97	0.76	0.24	0.7	0.25	0.87	0.92	0.42	0.99	0.83	0.95	0.9	0.41	0.91	0.64	0.5	-0.21	0.94	0.94	0.68	-0.02		0.91
Property Plant And Equipment Gross	0.9	0.52	0.81	0.93	0.76	0.4	0.66	0.04	0.81	0.95	0.53	0.88	0.73	0.86	0.91	0.51	0.84	0.65	0.54	-0.28	0.78	0.86	0.74	0.1	0.91

Click cells to compare fundamentals

Eagle Pharmaceuticals Account Relationship Matchups

Eagle Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	254.6M	253.2M	253.7M	406.2M	467.1M	490.4M
Short Long Term Debt Total	38.6M	37.1M	25.6M	62.5M	71.8M	41.6M
Other Current Liab	2.3M	3.1M	7.0M	85.8M	98.7M	103.7M
Total Current Liabilities	38.8M	38.1M	74.4M	111.1M	127.8M	134.1M
Total Stockholder Equity	179.2M	186.0M	176.5M	233.6M	268.6M	138.0M
Property Plant And Equipment Net	2.2M	2.1M	1.6M	1.2M	1.3M	2.3M
Current Deferred Revenue	21.7M	26.1M	20.7M	25.4M	29.2M	17.3M
Net Debt	(71.2M)	(66.1M)	(72.1M)	7.1M	6.4M	6.8M
Retained Earnings	72.5M	84.5M	75.9M	111.5M	128.2M	134.6M
Accounts Payable	5.5M	6.3M	16.4M	19.0M	21.8M	22.9M
Cash	109.8M	103.2M	97.7M	55.3M	63.6M	73.0M
Non Current Assets Total	75.1M	87.1M	81.1M	217.4M	250.0M	262.5M
Non Currrent Assets Other	3.9M	17.2M	10.3M	15.7M	18.1M	19.0M
Other Assets	13.9M	32.4M	29.1M	52.9M	60.8M	63.9M
Long Term Debt	38.2M	33.6M	25.1M	56.2M	64.6M	67.9M
Cash And Short Term Investments	109.8M	103.2M	97.7M	55.3M	63.6M	75.1M
Net Receivables	48.0M	51.1M	41.1M	72.4M	83.3M	87.5M
Common Stock Shares Outstanding	14.1M	13.8M	13.1M	13.1M	15.0M	14.9M
Liabilities And Stockholders Equity	254.6M	253.2M	253.7M	406.2M	467.1M	490.4M
Non Current Liabilities Total	36.6M	29.1M	2.9M	61.5M	70.7M	74.3M
Inventory	6.6M	8.1M	21.9M	47.8M	55.0M	57.7M
Other Current Assets	15.1M	1.6M	11.9M	13.2M	15.2M	8.2M
Other Stockholder Equity	106.7M	101.5M	100.7M	123.2M	110.8M	100.8M
Total Liab	75.4M	67.2M	77.3M	172.6M	198.5M	208.4M
Property Plant And Equipment Gross	2.2M	2.1M	7.6M	7.8M	8.9M	9.4M
Total Current Assets	179.4M	166.1M	172.6M	188.8M	217.1M	137.0M
Accumulated Other Comprehensive Income	(3.3M)	(4.3M)	(94K)	(1.1M)	(1.3M)	(1.3M)
Short Term Debt	6.3M	5M	8M	25.6M	7.2M	8.4M
Property Plant Equipment	2.2M	2.1M	1.6M	1.2M	1.3M	2.3M
Net Tangible Assets	123.8M	133.4M	126.0M	70.2M	80.7M	106.8M
Retained Earnings Total Equity	72.5M	84.5M	75.9M	111.5M	128.2M	134.6M
Capital Surpluse	278.5M	305.4M	325.8M	366.3M	421.2M	282.9M
Treasury Stock	(171.9M)	(203.9M)	(225.1M)	(243.1M)	(218.8M)	(207.9M)
Intangible Assets	15.6M	12.9M	10.7M	118.3M	136.1M	142.9M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Eagle Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Eagle Pharmaceuticals' short interest history, or implied volatility extrapolated from Eagle Pharmaceuticals options trading.

Pair Trading with Eagle Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eagle Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eagle Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Eagle Stock

0.49

TPST

Tempest Therapeutics Financial Report 8th of May 2024

Pair Corr

The ability to find closely correlated positions to Eagle Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eagle Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eagle Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eagle Pharmaceuticals to buy it.

The correlation of Eagle Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eagle Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eagle Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Eagle Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Eagle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eagle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eagle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eagle Pharmaceuticals Stock:

How To Invest In Eagle

Details

Is Eagle Stock a good investment?

Details

What is Eagle Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Eagle Stock analysis

When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Equity Valuation Check real value of public entities based on technical and fundamental data
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments

Is Eagle Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eagle Pharmaceuticals. If investors know Eagle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eagle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.87)

Earnings Share

0.85

Revenue Per Share

19.684

Quarterly Revenue Growth

(0.13)

Return On Assets

0.0663

The market value of Eagle Pharmaceuticals is measured differently than its book value, which is the value of Eagle that is recorded on the company's balance sheet. Investors also form their own opinion of Eagle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eagle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eagle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eagle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Eagle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eagle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eagle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eagle Depreciation Amortization and Accretion vs Issuance Purchase of Equity Shares Analysis

About Eagle Balance Sheet Analysis

Eagle Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Eagle Pharmaceuticals fundamental ratios Correlations

Eagle Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eagle Pharmaceuticals fundamental ratios Accounts

Pair Trading with Eagle Pharmaceuticals

Moving against Eagle Stock

Complementary Tools for Eagle Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 0.99	Cash
Total Liab	+ 0.99	Non Current Assets Total
Net Receivables	+ 0.98	Total Assets
Inventory	+ 0.98	Total Current Liabilities
Other Assets	+ 0.98	Non Current Assets Total
Total Liab	+ 0.97	Total Current Liabilities

Cash And Short Term Investments	- 0.74	Net Debt
Cash	- 0.74	Net Debt
Net Debt	- 0.56	Property Plant And Equipment Net
Other Stockholder Equity	- 0.54	Net Debt
Short Term Investments	- 0.53	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.53	Net Debt